{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:36:35Z","timestamp":1791221795036,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy of iloperidone for mania associated with bipolar I disorder and discuss its safety profile (eg, QTc prolongation, orthostatic hypotension, and metabolic adverse effects).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>Literature was identified using PubMed (1966-September 2024), OVID (1984-November 2024), and clinicaltrials.gov. Search terms included iloperidone, bipolar disorder, and mania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>The study included trials evaluating iloperidone for treating bipolar mania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>In one phase 3 study, iloperidone demonstrated significant improvement in mania symptoms at day 28 on all primary (ie, Young Mania Rating Scale) and secondary outcomes (Clinical Global Impression-Severity\/Change scales) compared to placebo. Iloperidone was well tolerated, with tachycardia, dizziness, dry mouth, alanine aminotransferase elevation, nasal congestion, increased weight, and somnolence reported as common adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison to existing drugs:<\/jats:title>\n                    <jats:p>Since there are no head-to-head studies comparing iloperidone with other second-generation antipsychotics for bipolar mania, other treatment considerations drive medication selection. Iloperidone is unavailable in a generic formulation; thus, its use will be associated with higher costs. It is dosed twice daily, which may negatively impact adherence. Iloperidone is associated with a moderate risk of QTc prolongation, metabolic adverse effects, and orthostatic hypotension, which will limit its use in certain patient populations. QTc prolongation is dose related, so drug interactions involving CYP2D6 and CYP3A4 inhibition can have serious consequences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In the pivotal trial, iloperidone was effective in treating adults with an acute manic or mixed episode associated with bipolar I disorder and was safe and well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241308287","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:46:42Z","timestamp":1736729202000},"page":"839-849","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["An Evaluation of Iloperidone for Mania in Bipolar I Disorder"],"prefix":"10.1177","volume":"59","author":[{"given":"Kelen","family":"Caskey","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-8682","authenticated-orcid":false,"given":"Leigh Anne","family":"Nelson","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administration, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2012-1693"},{"key":"e_1_3_2_3_2","unstructured":"American Psychiatric Association. Updates to DSM-5 criteria. Supplement to diagnostic and statistical manual of mental disorders fifth edition. Published September 2016. Accessed September 10 2024. https:\/\/www.psychiatry.org:443\/psychiatrists\/practice\/dsm\/updates-to-dsm\/updates-to-dsm-5-criteria-text"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.19"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.psy.0000151489.36347.18"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-020-1130-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000593"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12408"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12319"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17090972"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12609"},{"key":"e_1_3_2_12_2","unstructured":"Bipolar disorder: assessment and management. National Institute for Health and Care Excellence NICE. Published December 21 2023. Accessed December 11 2024. www.nice.org.uk\/guidance\/cg185"},{"key":"e_1_3_2_13_2","unstructured":"US Department of Veterans Affairs. VA\/DoD clinical practice guidelines management of bipolar disorder. Published 2023. Accessed December 3 2024. https:\/\/www.healthquality.va.gov\/guidelines\/mh\/bd\/"},{"key":"e_1_3_2_14_2","unstructured":"Golden J Kelleher J Moore D. Vanda pharmaceuticals\u2019 Fanapt\u00ae (iloperidone) receives U.S. FDA approval for the acute treatment of bipolar I disorder. PR Newswire. Published April 2 2024. Accessed September 1 2024. https:\/\/www.prnewswire.com\/news-releases\/vanda-pharmaceuticals-fanapt-iloperidone-receives-us-fda-approval-for-the-acute-treatment-of-bipolar-i-disorder-302106405.html"},{"key":"e_1_3_2_15_2","unstructured":"FANAPT\u00ae (iloperidone) [package insert]. Vanda Pharms Inc. Published April 2024. Accessed September 10 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=022192"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18372"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14966"},{"key":"e_1_3_2_18_2","unstructured":"Rush AJ First MB Blacker D. Handbook of Psychiatric Measures. 2nd ed. American Psychiatric Association; 2008. Accessed September 26 2024. https:\/\/www.appi.org\/Products\/Measures-and-Rating-Scales\/Handbook-of-Psychiatric-Measures-Second-Edition#"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000764"},{"key":"e_1_3_2_20_2","unstructured":"Tabacova S Rosloff B Laughren T Updegraff K. Pharmacology\/Toxicology Review and Evaluation: Iloperidone. Center for Drug Evaluation and Research; 2007. Accessed December 11 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022192s000_PharmR_P1.pdf"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.03.002"},{"key":"e_1_3_2_22_2","unstructured":"Cutler AJ Kalali AH Weiden PJ Hamilton J Wolfgang CD. Four-week double-blind placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. PubMed. Accessed September 23 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/18334909\/"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181694f5a"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181692787"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31827c0314"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001318"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2404"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00625-3"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000850"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60873-8"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01334-4"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0345-4"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241308287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241308287","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241308287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:58Z","timestamp":1777374838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241308287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/10600280241308287"],"URL":"https:\/\/doi.org\/10.1177\/10600280241308287","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}